LifeTech Scientific (HKSE:01302) ROCE % : 7.84% (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is LifeTech Scientific ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. LifeTech Scientific's annualized ROCE % for the quarter that ended in Jun. 2024 was 7.84%.

LifeTech Scientific ROCE % Historical Data

The historical data trend for LifeTech Scientific's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeTech Scientific ROCE % Chart

LifeTech Scientific Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

13.74

14.11

13.20

12.48

4.97

LifeTech Scientific Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															14.27	11.81	13.31	-2.38	7.84

LifeTech Scientific ROCE % Calculation

LifeTech Scientific's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	192.836	/	( ( (4120.792 - 652.982)	+	(5136.784 - 842.358) )	/ 2 )
	=	192.836	/	( (3467.81	+	4294.426)	/ 2 )
	=	192.836	/	3881.118
	=	4.97 %

LifeTech Scientific's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	336.796	/	( ( (5136.784 - 842.358)	+	(5188.471 - 889.789) )	/ 2 )
	=	336.796	/	( ( 4294.426	+	4298.682 )	/ 2 )
	=	336.796	/	4296.554
	=	7.84 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

LifeTech Scientific (HKSE:01302) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

LifeTech Scientific ROCE % Related Terms

Thank you for viewing the detailed overview of LifeTech Scientific's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

LifeTech Scientific Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LifeTech Scientific Corp (HKSE:01302) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

81X:Germany

Address

No. 22, Keji 12th Road South, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063

Website

http://www.lifetechmed.com

LifeTech Scientific Corp develops and manufactures also responsible for marketing of of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of revenue from China.

Executives

Xie Yuehui	2201 Interest of corporation controlled by you
Xianjian Advanced Technology Limited	2101 Beneficial owner
Futu Trustee Limited	2301 Trustee
Xie Yuehui	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Bank Of Communications Trustee Limited	2301 Trustee
Hhlr Fund, L.p.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner

LifeTech Scientific Headlines

No Headlines